Cargando…
Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR(−/−) Mice
Astragaloside IV (AS-IV) is the main active compound of Astragalus membranaceus. In this study, we investigated whether AS-IV could attenuate atherosclerosis and hepatic steatosis in LDLR−/−mice and its potential mechanisms. After 12 weeks of high fat diet, the LDLR−/−mice were randomly divided into...
Autores principales: | Zhang, Yifan, Du, Min, Wang, Jiarou, Liu, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899310/ https://www.ncbi.nlm.nih.gov/pubmed/35264962 http://dx.doi.org/10.3389/fphar.2022.828161 |
Ejemplares similares
-
Tanshinone IIA alleviates atherosclerosis in LDLR(−/−) mice by regulating efferocytosis of macrophages
por: Wang, Jiarou, et al.
Publicado: (2023) -
Guanxinkang Decoction Attenuates the Inflammation in Atherosclerosis by Regulating Efferocytosis and MAPKs Signaling Pathway in LDLR(−/−) Mice and RAW264.7 Cells
por: Zhang, Yifan, et al.
Publicado: (2021) -
Astragaloside IV Improves High-Fat Diet–Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway
por: Liu, Ying-Li, et al.
Publicado: (2021) -
Salvianolic acid B attenuates the inflammatory response in atherosclerosis by
regulating MAPKs/ NF-κB signaling pathways in LDLR-/- mice and RAW264.7
cells
por: Zhang, Yifan, et al.
Publicado: (2022) -
Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)